GnRH-test after high-dose MPA in women with post-menopausal LH-preferential release.
The association between post-climacteric LH-preferential release after GnRH-Test and the occurrence of benign or malignant estrogen dependent diseases makes the Authors evaluate the variations induced in such type of hypophyseal response by MPA, administered in the same doses as in the hormonal therapy of cancer. MPA lowered both the basal gonadotropin secretion and the amplitude of the response to the neurohormone, suggesting the hypothesis of a possible direct inhibitory action of the hormone on the hypophysis. The persistence of LH-preferential release after the ten day treatment with MPA 200 mg daily might be explained by the lack of modifications induced by the hormone on the levels of cytoplasmic E2-receptors, on which seems based LH-preferential release.
D005260:Female; D007987:Gonadotropin-Releasing Hormone; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism*; D008525:Medroxyprogesterone / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D008593:Menopause; D010902:Pituitary Gland / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000187:drug effects; D011974:Receptors, LH; D013268:Stimulation, Chemical; D013997:Time Factors
D011956:Receptors, Cell Surface; D011974:Receptors, LH; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone